Literature DB >> 23661334

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Ian J Majewski1, Lorenza Mittempergher, Nadia M Davidson, Astrid Bosma, Stefan M Willems, Hugo M Horlings, Iris de Rink, Liliana Greger, Gerrit K J Hooijer, Dennis Peters, Petra M Nederlof, Ingrid Hofland, Jeroen de Jong, Jelle Wesseling, Roelof J C Kluin, Wim Brugman, Ron Kerkhoven, Frank Nieboer, Paul Roepman, Annegien Broeks, Thomas R Muley, Jacek Jassem, Jacek Niklinski, Nico van Zandwijk, Alvis Brazma, Alicia Oshlack, Michel van den Heuvel, René Bernards.   

Abstract

Oncogenic fusion genes that involve kinases have proven to be effective targets for therapy in a wide range of cancers. Unfortunately, the diagnostic approaches required to identify these events are struggling to keep pace with the diverse array of genetic alterations that occur in cancer. Diagnostic screening in solid tumours is particularly challenging, as many fusion genes occur with a low frequency. To overcome these limitations, we developed a capture enrichment strategy to enable high-throughput transcript sequencing of the human kinome. This approach provides a global overview of kinase fusion events, irrespective of the identity of the fusion partner. To demonstrate the utility of this system, we profiled 100 non-small cell lung cancers and identified numerous genetic alterations impacting fibroblast growth factor receptor 3 (FGFR3) in lung squamous cell carcinoma and a novel ALK fusion partner in lung adenocarcinoma.
© 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661334     DOI: 10.1002/path.4209

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  57 in total

Review 1.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 3.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

4.  Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Authors:  Julie W Reeser; Dorrelyn Martin; Jharna Miya; Esko A Kautto; Ezra Lyon; Eliot Zhu; Michele R Wing; Amy Smith; Matthew Reeder; Eric Samorodnitsky; Hannah Parks; Karan R Naik; Joseph Gozgit; Nicholas Nowacki; Kurtis D Davies; Marileila Varella-Garcia; Lianbo Yu; Aharon G Freud; Joshua Coleman; Dara L Aisner; Sameek Roychowdhury
Journal:  J Mol Diagn       Date:  2017-08-09       Impact factor: 5.568

Review 5.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

Review 6.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

7.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

Authors:  Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 8.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

9.  Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Authors:  Ellen M Beauchamp; Brittany A Woods; Austin M Dulak; Li Tan; Chunxiao Xu; Nathanael S Gray; Adam J Bass; Kwok-kin Wong; Matthew Meyerson; Peter S Hammerman
Journal:  Mol Cancer Ther       Date:  2013-12-02       Impact factor: 6.261

Review 10.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Authors:  Alison M Schram; Matthew T Chang; Philip Jonsson; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.